Alembic Pharmaceuticals Ltd (ALEM.NS)
Tue, Nov 7 2017
* Says U.S. formulations business continues to face price erosion on some key products; India branded business showing signs of recovery
* Says co buys U.S. based generic drug developer Orit Laboratories LLC Source text: http://bit.ly/2z3AKCI Further company coverage:
* Alembic Pharmaceuticals - gets EU GMP certificate for audit conducted at its formulation facility at Panelav from 8th to 10th Aug Source text for Eikon: Further company coverage:
* Says sold Baddi, Solan plant to Scott Edil Pharmacia Ltd on slump sale basis
BRIEF-Alembic Pharmaceuticals sells formulations manufacturing facility at Baddi to Scott Edil Pharmacia
* Alembic pharmaceuticals says sold on slump sale basis its formulations manufacturing facility at Baddi, dist. Solan to Scott Edil Pharmacia Limited Source text for Eikon: Further company coverage:
* Says there was a fire incident at Algerian joint venture plant at Constantine, Algeria Constantine, Algeria
* Says Alembic Pharmaceuticals Limited receives USFDA approval for Doxycycline Capsules USP, 75 mg and 100 Mg.
* June quarter consol profit after tax 633.8 million rupees versus 1.04 billion rupees year ago
* Says received U.S. food & drug administration (USFDA) approval for olmesartan medoxomil and amlodipine tablets Source text for Eikon: Further company coverage:
* Says alembic pharmaceuticals receives USFDA tentative approval for Dabigatran Etexilate Capsules, 150 mg.